Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 4, 2006, Pages 723-732

  Zürcher, Thomas ^a   Yates, Phillip J ^a   Daly, Janet ^a,c   Sahasrabudhe, Anjali ^b   Walters, Matthew ^a,d   Dash, Laura ^a   Tisdale, Margaret ^a   McKimm Breschkin, Jennifer L ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b CSIRO   (Australia)

^c ANIMAL HEALTH TRUST   (United Kingdom)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Baculovirus; Drug resistance; Oseltamivir; Reverse genetics

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ADENINE; GUANINE; N ACETYLNEURAMINIC ACID DERIVATIVE; OSELTAMIVIR; PERAMIVIR; TYROSINE; VIRUS SIALIDASE; ZANAMIVIR;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; GENE MUTATION; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS; INSECT CELL; NONHUMAN; THERMOSTABILITY; VIROGENESIS; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS TYPING; VIRUS VIRULENCE; WILD TYPE;

ANIMALS; ANTIVIRAL AGENTS; BACULOVIRIDAE; CELL LINE; CELLS, CULTURED; DOGS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; MUTATION; NEURAMINIDASE; PYRANS; SIALIC ACIDS; SPODOPTERA; VIRUS REPLICATION; ZANAMIVIR;

EID: 33748702675     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl321     Document Type: Article

References (41)

1. Varghese JN, McKimm-Breschkin JL, Caldwell JB et al. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992; 14: 327-32.
2. von Itzstein M, Wu WY, Kok GB et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418-23.
3. Kim CU, Lew W, Williams MA et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site:dEsign, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997; 119: 681-90.
4. Babu YS, Chand P, Bantia S et al. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 2000; 43: 3482-6.
5. BioCryst. Peramivir Today. http://www.biocryst.com/pdf/ peramivirfacts.pdf. (5 December 2005, date last accessed).
6. Smith BJ, McKimm-Breschkin JL, McDonald M et al. Structural studies of the resistance of influenza virus neuramindase to inhibitors. J Med Chem 2002; 45: 2207-12.
7. Varghese JN, Smith PW, Sollis SL et al. Drug design against a shifting target: A structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 1998; 6: 735-46.
8. Gubareva LV, Bethell R, Hart GJ et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996; 70: 1818-27.
9. Gubareva LV, Robinson MJ, Bethell RC et al. Catalytic and framework mutations in the neurominidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71: 3385-90.
10. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998; 72: 2456-62.
11. Blick TJ, Tiong T, Sahasrabudhe A et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995; 214: 475-84.
12. Barnett JM, Cadman A, Burrell FM et al. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 1999; 265: 286-95.
13. Cheam AL, Barr IG, Hampson AW et al. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. Antiviral Res 2004; 63: 177-81.
14. Staschke KA, Colacino JM, Baxter AJ et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 1995; 214: 642-6.
15. Gubareva LV, Matrosovich MN, Brenner MK et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178: 1257-62.
16. McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: Detection, incidence, and implications of drug resistance. Treat Respir Med 2005; 4: 107-16.
17. Le QM, Kiso M, Someya K et al. Avian flu: Isolation of drug-resistant H5N1 virus. Nature 2005; 437: 1108.
18. Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 2004; 364: 759-65.
19. Ward P, Small I, Smith J et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55 Suppl 1: I5-21.
20. Jackson D, Barclay W, Zurcher T. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 2005; 55: 162-9.
21. Wetherall NT, Trivedi T, Zeller J et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: Report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003; 41: 742-50.
22. Abed Y, Goyette N, Boivin G. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir Ther 2004; 9: 577-81.
23. Jackson D, Cadman A, Zurcher T et al. A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA. J Virol 2002; 76: 11744-7.
24. Jones MH, Learned RM, Tjian R. Analysis of clustered point mutations in the human ribosomal RNA gene promoter by transient expression in vivo. Proc Natl Acad Sci USA 1988; 85: 669-73.
25. Fortes P, Beloso A, Ortin J. Influenza virus NS1 protein inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transport. EMBO J 1994; 13: 704-12.
26. Mena I, de la Luna S, Albo C et al. Synthesis of biologically active influenza virus core proteins using a vaccinia virus-T7 RNA polymerase expression system. J Gen Virol 1994; 75: 2109-14.
27. Goto H, Bethell RC, Kawaoka Y. Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2, 4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 1997; 238: 265-72.
28. Buxton RC, Edwards B, Juo RR et al. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem 2000; 280: 291-300.
29. McKimm-Breschkin JL, McDonald M, Blick TJ et al. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino. Neu5Ac2en leads to instability of the enzyme. Virology 1996; 225: 240-2.
30. Webster RG, Air GM, Metzger DW et al. Antigenic structure and variation in an influenza virus N9 neuraminidase. J Virol 1987; 61: 2910-6.
31. McKimm-Breschkin JL, Caldwell JB, Guthrie RE et al. A new method for the purification of the influenza A virus neuraminidase. J Virol Methods 1991; 32: 121-4.
32. McKimm-Breschkin J, Trivedi T, Hampson A et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47: 2264-72.
33. Ives J, Carr J, Roberts NA et al. An oseltamivir treatment-selected influenza A:N2 virus with a R292K mutation in the neuraminidase gene has reduced infectivity in vivo. J Clinical Virol 2000; 18: 251-69.
34. Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother 2002; 46: 3809-16.
35. Tisdale M. Monitoring of viral susceptibility: New challenges with the development of influenza NA inhibitors. Rev Med Virol 2000; 10: 45-55.
36. McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res 2000; 47: 1-17.
37. Varghese JN, Colman PM, van Donkelaar A et al. Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases. Proc Natl Acad Sci USA 1997; 94: 11808-12.
38. Molla A, Kati W, Carrick R et al. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J Virol 2002; 76: 5380-6.
39. Tulip WR, Varghese JN, Baker AT et al. Refined atomic structures of N9 subtype influenza virus neuraminidase and escape mutants. J Mol Biol 1991; 221: 487-97.
40. Baker AT, Varghese JN, Laver WG et al. Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins 1987; 2: 111-7.
41. Varghese JN, Epa VC, Colman PM. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci 1995; 4: 1081-7.